Scholarlink

Background <p>Neuroendocrine carcinoma of the esophagus is a highly aggressive and rare type of cancer, making diagnosis and treatment challenging for clinicians. The current guidelines provide conflicting recommendations, and no standardized treatment protocol is available. We aim to deliver a systematic review of esophageal neuroendocrine carcinoma, including patient characteristics, treatment options, and prognostic factors.</p> Methods <p>PubMed, Web of Science, Scopus, and Embase were searched up to May 2025 to retrieve the relevant studies containing at least 5 cases that reported treatment details, survival outcomes, or patient characteristics. Meta-analysis was conducted using a random-effects model for prognostic factors reported in at least three studies. We calculated survival information using the Kaplan–Meier method and estimated the median 1, 3, and 5-year survival rates in studies with available individual data that did not directly report the survival outcomes.</p> Results <p>Overall, 24 articles with 1618 cases were included. The median overall survival of patients was 22.5 months, with median 1-, 3-, and 5-year survival rates of 76%, 47%, and 34%, respectively. Distant metastasis (HR, 2.68; 95% CI: 2.10 to 3.41; <i>P</i> &lt; .01) and lymph node involvement (HR, 1.44; 95% CI: 1.04 to 1.99; <i>P</i> = .02) were significantly associated with poor prognosis. Surgery in selected cases improved the survival outcomes with an HR of 0.36 (95% CI, 0.28 to 0.46; <i>P</i> = &lt; .01).</p> Conclusion <p>The current study demonstrates that distant metastasis and lymph node involvement are significant predictors of poor prognosis in esophageal neuroendocrine carcinoma. Survival outcomes were comparable between patients with resectable tumors undergoing surgery and those receiving definitive chemoradiotherapy, both of which outperformed chemotherapy alone or no treatment. While adjuvant therapy may improve survival in node-positive cases post-surgery, this evidence remains limited by small sample sizes in existing studies. Further large-scale, prospective studies are needed to validate optimal treatment strategies, particularly the role of multimodal therapy in advanced disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neuroendocrine carcinoma of esophagus: systematic review and meta-analysis of case series

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Seyed Morteza Pourfaraji,
  • Amirmohsen Jalaeefar,
  • Fatemeh Ojaghi Shirmard,
  • Dorsa Salabat,
  • Sara Mohammadi,
  • Narjes Mohammadzadeh

摘要

Background

Neuroendocrine carcinoma of the esophagus is a highly aggressive and rare type of cancer, making diagnosis and treatment challenging for clinicians. The current guidelines provide conflicting recommendations, and no standardized treatment protocol is available. We aim to deliver a systematic review of esophageal neuroendocrine carcinoma, including patient characteristics, treatment options, and prognostic factors.

Methods

PubMed, Web of Science, Scopus, and Embase were searched up to May 2025 to retrieve the relevant studies containing at least 5 cases that reported treatment details, survival outcomes, or patient characteristics. Meta-analysis was conducted using a random-effects model for prognostic factors reported in at least three studies. We calculated survival information using the Kaplan–Meier method and estimated the median 1, 3, and 5-year survival rates in studies with available individual data that did not directly report the survival outcomes.

Results

Overall, 24 articles with 1618 cases were included. The median overall survival of patients was 22.5 months, with median 1-, 3-, and 5-year survival rates of 76%, 47%, and 34%, respectively. Distant metastasis (HR, 2.68; 95% CI: 2.10 to 3.41; P < .01) and lymph node involvement (HR, 1.44; 95% CI: 1.04 to 1.99; P = .02) were significantly associated with poor prognosis. Surgery in selected cases improved the survival outcomes with an HR of 0.36 (95% CI, 0.28 to 0.46; P = < .01).

Conclusion

The current study demonstrates that distant metastasis and lymph node involvement are significant predictors of poor prognosis in esophageal neuroendocrine carcinoma. Survival outcomes were comparable between patients with resectable tumors undergoing surgery and those receiving definitive chemoradiotherapy, both of which outperformed chemotherapy alone or no treatment. While adjuvant therapy may improve survival in node-positive cases post-surgery, this evidence remains limited by small sample sizes in existing studies. Further large-scale, prospective studies are needed to validate optimal treatment strategies, particularly the role of multimodal therapy in advanced disease.